Skip to Content


Active substance(s): CICLOSPORIN

PDF options:  View Fullscreen   Download PDF

PDF Transcript



Capsorin 100 mg/ml oral solution.


Oral solution containing 100 mg of ciclosporin per ml (microemulsion).
Excipient(s) with known effect:
Each ml contains 100.00 mg of Ethanol, anhydrous.
For the full list of excipients, see section 6.1.


Oral solution.
Clear and transparent solution.




Therapeutic indications
Organ transplantation
Prevention of graft rejection following kidney, liver, heart, combined heart-lung, lung
or pancreas transplants.
Treatment of transplant rejection in patients previously receiving other
immunosuppressive agents.
Bone marrow transplantation
Prevention of graft rejection following bone marrow transplantation.
Prevention or treatment of graft-versus-host disease (GVHD).
Other indications
Nephrotic syndrome
Adults and children with steroid dependent or steroid resistant nephrotic syndrome
due to glomerular disorders such as glomerular minimum changes, focal segmental
glomerulosclerosis or membranous glomerulonephritis. It can also be used to
maintain steroid-induced remission, allowing to suspend steroids.
Rheumatoid arthritis

Indicated for the treatment of severe, active rheumatoid arthritis in patients in whom
classical, disease modifying anti-rheumatic drugs (DMARD’s) are inappropriate or
Treatment of severe forms of psoriasis in patients in whom conventional therapy is
inappropriate or ineffective.
Atopic dermatitis
Capsorin is indicated in patients with severe atopic dermatitis in whom conventional
therapy is ineffective.


Posology and method of administration

The daily dose of Ciclosporin should always be divided in 2 doses.
In transplant patients routine monitoring of the ciclosporin blood levels should be
performed in order to avoid the risk of adverse reactions (if blood levels are too high)
and organ rejection (if blood levels are too low).
Due to possible differences in bioavailability patients should not be transferred to or
from other oral formulations of ciclosporin without appropriate close monitoring of
ciclosporin blood concentrations, serum creatinine levels and blood pressure. For this
reason it may be appropriate to prescribe by brand.
For drug level monitoring, whole blood is preferred, measured by a specific analytical
method. A number of methods that measure unaltered ciclosporin (HPLC, specific
monoclonal specific radioimmunoassays) as well as unspecific methods that also
measure some metabolites have been developed for determining ciclosporin levels:
The results of the various determination methods are not interchangeable.
Determination of ciclosporin levels by means of specific monoclonal antibodies or by
HPLC is to be given preference. Target concentration ranges depend on organ type,
time after transplantation and immunosuppressive regimen.
It should be noted that other factors besides ciclosporin blood level can affect the
clinical condition of the patient. The results are therefore intended only as a guide for
dosing and should be used together with other clinical and laboratory parameters.
A higher oral dose of ciclosporin or an intravenous dose may be necessary if
absorption is impaired by gastrointestinal disturbances.
Organ transplantation
Treatment with ciclosporin is initiated within 12 hours prior to surgery with a dose of
10-15 mg/kg given in two divided doses. This daily dose is continued 1-2 weeks
following surgery whereupon the daily dose is gradually reduced in agreement with
the blood concentration to a maintenance dose of approximately 2-6 mg/kg given in
two divided doses.
When ciclosporin is used with other immunosuppressants (e.g. with corticosteroids or
in poly- therapy), a lower dose is administered (e.g. initially 3-6 mg/kg given in 2
divided doses).
Bone marrow transplantation
For the prevention of graft-versus-host-disease (GVHD), ciclosporin is commonly
used initially, short-term, in combination with methotrexate. The optimum dose

should be adjusted individually. In general, treatment should be initiated 1 to 2 days
before bone marrow transplantation with intravenous ciclosporin (dosage 2.5 to 5
mg/kg/day). This is replaced by oral administration as soon as patients are able to
tolerate oral medication (generally at 12.5 mg/kg/day). Oral treatment should be
continued for at least 3-6 months, before gradual dose reduction and eventual
Alternative treatment regimes are intravenous ciclosporin as mono therapy at 5
mg/kg/day (day 1 to day 3) and 3 mg/kg/day (day 4 to day 14) or combination therapy
with intravenous ciclosporin at 3-5 mg/kg/day and corticosteroids. In these cases,
treatment should also be changed to the oral route as soon as possible and continued
over a longer period.
If Ciclosporin is used to initiate therapy, the recommended dose is 12.5 to 15
mg/kg/day given in 2 divided doses, starting on the day before transplantation.
Some patients may experience GVHD after discontinuation of ciclosporin treatment,
but usually respond positively to repeated treatment. A low dose of Ciclosporin can
be used for mild, chronic GVHD.
Nephrotic syndrome
For induction of remission the recommended oral dose is 5 mg/kg/day given in two
divided doses for adults and 6 mg/kg/day for children, if renal function is normal. In
patients with reduced renal function, the initial dose should not exceed 2.5
Appropriate monitoring of the ciclosporin level pre-dose to avoid overdose in
children is recommended.
In focal segmental glomerulosclerosis , a combination of Ciclosporin and
corticosteroids may be of benefit.
In the absence of efficacy after 3 months treatment for minimal change and focal
segmental glomerulosclerosis or 6 months treatment for membranous
glomerulonephritis, Ciclosporin therapy should be discontinued.
The dose should be individually adjusted according to efficacy (proteinuria) and
safety (mainly serum creatinine), but should not exceed 5 mg/kg/day for adults and 6
mg/kg/day for children.
In maintenance treatment the dose is slowly reduced to the lowest therapeutically
effective level.
Rheumatoid arthritis
For the first 6 weeks of therapy, the recommended dose is 2.5 mg/kg/day, given in 2
divided doses. The dose may be decreased depending on tolerance. The daily dose
may be increased gradually, if the clinical effect is considered insufficient. Normally,
the daily dose may not exceed 4 mg/kg/day. In individual cases, the dose may be
increased up to 5 mg/kg/day. If the dose is increased too soon, there is a risk of
For maintenance, the dosage should be adjusted individually to the lowest effective

Low-dose corticosteroids and/or non-steroidal anti-inflammatory drugs can be used in
combination with ciclosporin (see also “4.5 Interaction with other medicinal products
and other forms of interaction”).
Treatment of this condition is individually adjusted since the disease varies greatly.
For induction of remission, the recommended initial dose is 2.5 mg/kg/day orally
given in 2 divided doses. If no improvement is seen after 1 month, the daily dose can
gradually be increased to maximum 5 mg/kg. The treatment should be discontinued in
patients with psoriasis lesions which do not show a sufficient response within 6
weeks at 5 mg/kg/day, or where the clinically effective dose is not compatible with
the established safety guidelines.
An initial dose of 5 mg/kg/day is justified in patients whose condition requires rapid
improvement. When a satisfactory response is achieved, treatment with Ciclosporin
can be discontinued and a possible relapse can be treated with Ciclosporin at the
previous clinically effective dose. Some patients may require continuous maintenance
In maintenance treatment the dose is individually titrated to the lowest clinically
effective level and the dose should not exceed 5 mg/kg/day given in two divided
Atopic dermatitis
Treatment of this condition is individually adjusted, since the disease varies greatly.
The recommended dose is 2.5-5 mg/kg/day orally given in 2 divided doses, for a
maximum of 8 weeks. If an initial dose of 2.5 mg/kg/day does not give a satisfactory
result within two weeks, the daily dose can be increased to maximum of 5 mg/kg. In
very severe cases, the disease can be controlled with an initial dose of 5 mg/kg per
day. When a satisfactory response is achieved, the dose should be gradually reduced
and treatment discontinued.
Dosage in renal insufficiency
Specific investigations have not been performed on the pharmacokinetics of
ciclosporin in transplant patients with impaired renal function. Special caution is
required if a rapid rise in serum creatinine occurs (even within the normal range) after
starting treatment with Ciclosporin. A rise in serum creatinine or fall in creatinine
clearance may also be the expression of an acute rejection reaction, particularly after
renal transplantation. Initiation of treatment with Ciclosporin in existing renal
dysfunction and subsequent dose adjustment should only be undertaken after careful
consideration of the benefits and risks, taking into account the overall clinical picture
and ciclosporin blood levels.
For patients with nephrotoxic syndrome and moderately impaired renal function
(baseline values of serum creatinine in adults <200 µmol/L, in children <140
µmol/L), an initial dose of 2.5 mg ciclosporin/kg body weight per day should not be
exceeded. Patients must be monitored closely.
Dosage in impaired hepatic function
Impaired liver function may considerably modify the pharmacokinetics of ciclosporin
in some cases. Blood concentrations of ciclosporin (cmin) must be monitored closely
in patients with impaired hepatic function and the dose adjusted accordingly.
In psoriasis, administration of Ciclosporin should be terminated if liver enzymes and
bilirubin levels are twice the baseline values.
In nephrotic syndrome patients with severe liver function disturbances, the initial
dose should be decreased by 25% to 50%.

There is limited experience with the use of ciclosporin in the elderly, but no special
problems have been seen at the recommended dose. However, factors associated with
ageing, such as impaired renal function, necessitate careful supervision and possible
dosage adjustment.
Paediatric population
Experience in children is limited. However, ciclosporin has been used at the
recommended dose for children from 1 year without special problems. In several
studies children needed a higher dose of ciclosporin per kg body weight than adults
and they tolerated the higher dose although at dosages above the upper end of the
recommended range children seem to be more susceptible to fluid retention,
convulsions and hypertension. This responds to dosage reduction.
Method of administration
The dose range is intended only as a guide Routine monitoring of ciclosporin blood
level is required in order to achieve the optimal therapeutic concentration for
individual patients. Monitoring can be done by means of a RIA method based on
monoclonal antibodies.
The total daily dose should always be administered in tow divided doses. The divided
doses should always be administered at the same time of day and the times between
single doses should be approximately equivalent. Therefore, it is recommended to
take the two divided doses in the morning and in the evening.
Ciclosporin can be administered with food or alone.
Switching from other oral ciclosporin preparations to Ciclosporin
In order to switch patients from other oral ciclosporin preparations to Ciclosporin,
ciclosporin trough blood levels, serum creatinine levels, and blood pressure should be
checked prior to the switch (i.e., while using other oral ciclosporin preparations). The
patient should be switched to the same daily dose of Ciclosporin that was used for the
prior ciclosporin preparation (mg per mg conversion). It is recommended that
ciclosporin trough levels, serum creatinine, and blood pressure be checked after 4 - 7
days. If necessary, the dose of Ciclosporin should be adjusted accordingly. Additional
check-ups may be necessary in the first two months following the switch (e. g., weeks
2, 4, and 8) and the dose adjusted accordingly.
The Oral Solution should be diluted preferentially with orange juice or apple juice.
However, it may also be taken with others non-alcoholic beverages, according to
individual taste. The oral solution should be stirred well immediately before being
Owing to its possible interference with the P450-dependent enzyme system,
grapefruit juice should not be used as a diluent. The measuring device should not
come into contact with the diluent. The measuring device should not be rinsed with
water, alcohol or any other liquid. If it is necessary to clean the measuring device, the
outside should be wiped with a dry tissue. (see section 6.6)


• Hypersensitivity to the active substance or to any of the excipients listed in section

• Ciclosporin is contra-indicated in psoriatic and atopic dermatitis patients with
abnormal renal function, uncontrolled hypertension, uncontrolled infections or any
kind of malignancy other than that of the skin (see section 4.4 Precautions).
• Ciclosporin is contra-indicated in rheumatoid arthritis patients with abnormal renal
function, uncontrolled hypertension, uncontrolled infections or any kind of
• Renal function disorders except in patients with nephrotic syndrome and milmoderate renal insufficiency
• Ciclosporin is contra-indicated in psoriasis patients receiving PUVA, UVB, coal tar,
radiation therapy and other immunossupressants
• Ciclosporin is contra-indicated in nephrotic syndrome patients with uncontrolled
hypertension, uncontrolled infections or any kind of malignancy
• Ciclosporin should not be used to treat rheumatoid arthritis in patients under the age
of 18 years.
• Concomitant use of tacrolimus is specifically contraindicated.
• Concomitant use of Hypericum perforatum (St. John’s Wort) drastically reduces the
plasma concentration of ciclosporin. This may result in a loss of therapeutic effect
(see section 4.5)
• Concomitant use of rosuvastatin is specifically contraindicated.


Special warnings and precautions for use
Capsorin should be prescribed only by physicians specialising in organ
transplantation, dermatology, nephrology or rheumatology. Patients should be
monitored in facilities with sufficient laboratory capacity and supporting medical
resources. The responsible physician should have all the available information in
preparation for the follow-up patients.
Capsorin should not be given in combination with other calcineurin inhibitors such as
tacrolimus, since this can be expected to lead to an increase in adverse effects (see
also 4.5 Interactions with other medicinal products and other forms of interactions)
without an improvement in efficacy.
In patients being given Capsorin, the use of potassium-sparing diuretics, medicinal
products containing potassium, ACE inhibitors, angiotensin-II-receptor antagonists
and a high intake of potassium with food should be avoided
Grapefruit juice may elevate the blood levels of ciclosporin by interacting with the
cytochrome-P450 system. The extent of these changes of ciclosporin levels in the
blood, however, differs in individual cases and is not predictable. Therefore,
grapefruit juice should not be taken in conjunction with Capsorin.
The use of medicinal products that can cause gingival hyperplasia (e. g. nifedipine)
should be avoided in patients who develop gingival proliferation under Capsorin (see
“4.8 Undesirable effects”).
When using inactivated vaccines or toxoid vaccines, the immune response should
always be controlled by means of titer determination (see “4.5 Interaction with other
medicinal products and other forms of interaction
Caution should be exercised in patients with hyperuricaemia since ciclosporin may
further elevate uric acid levels.

Capsorin may impair renal function. For this reason, a reliable creatinine baseline
value must be established prior to therapy with Capsorin. In the first three months of
treatment, the serum creatinine and serum urea values must be checked every two
In the event that kidney transplant patients who have very high ciclosporin levels in
the blood present with continuously worsening renal function values and if the latter
do not respond to a corresponding dose reduction, more extensive diagnostic tests
should be conducted, e. g. a kidney biopsy.
Capsorin may also impair liver function. For this reason the parameters for liver
function should be checked on a routine basis.
Since ciclosporin may on occasion precipitate hyperkalaemia or hypomagnesaemia or
exacerbate existing electrolytic disturbances of this kind, it is recommended serum
potassium and magnesium levels be monitored, particularly in patients with marked
renal dysfunction.
During treatment with ciclosporin, a routine blood pressure check is required (see
“4.8. Undesirable effects”). Treatment with ciclosporin should be discontinued is
hypertension cannot be controlled with appropriate hypertensive treatment.
When taking cyclosporine, a reversible elevation of blood lipids may occur. For this
reason it is recommended that blood lipid values be determined prior initiating
treatment and following the first month of treatment. Should blood lipids become
elevated, the intake of fats with food should be restricted and/or the cyclosporine dose
should be reduced.
Routine dental check-ups (e. g. every three months) are recommended. In order to
preclude or reduce gingival hyperplasia, teeth should be cleaned professionally and
the patient should be instructed about measures necessary for personal dental hygiene.
Under ciclosporin treatment, there is an increased frequency of skin tumours. For this
reason, patients should be warned against unnecessary radiation from the sun. A
routine examination of the skin as well as histological examination of suspicious
alterations is recommended.
Particular caution is advised in patients with untreated acute infections.
The routine determination of the minimum ciclosporin concentration in whole blood
is an important safety measure within the scope of therapy monitoring in transplant
patients (see “4.2 Posology and method of administration” under “Organ
It should be taken into account that the determination of the ciclosporin levels in
whole blood, plasma, or serum is only one of the factors contributing to the clinical
assessment of the patient’s status. Therefore, blood cyclosporine levels should only
serve as a reference for treatment and are to be supplemented by additional clinical
and laboratory parameters.
Capsorin may increase the risk of benign intracranial hypertension. Patients
presenting with signs of raised intracranial pressure should be investigated and if

benign intracranial hypertension is diagnosed, ciclosporin should be withdrawn due to
the possible risk of permanent visual loss.

Further precautions in nephrotic syndrome
Since ciclosporin may reduce the renal function, frequent monitoring is necessary and
if the serum creatinine levels are more than 30% above baseline in more than one
measurement, the dose of ciclosporin should be reduced by 25-50%. Patients with
abnormal baseline for renal function should be treated initially with 2.5 mg/kg/day
and monitored carefully.
It should be noted that in some nephrotic syndrome itself can cause alterations in
renal function. Thus, structural kidney alterations have been observed in association
with ciclosporin treatment, without an increase in serum creatinine levels. Renal
biopsy is indicated in patients treated with ciclosporin for more than one year to
access the progression of renal disease and the extent of any ciclosporin-associated
changes in renal morphology that may co-exist.
In patients with nephrotic syndrome treated with immunosuppressants (including
ciclosporin), there have been reports of malignant growths (including Hodgkin's
Long-term data on ciclosporin in the treatment of nephrotic syndrome are limited.
However, in clinical trials patients have received treatment for 1 to 2 years. Longterm treatment may be considered if there has been a significant reduction in
proteinuria with preservation of creatinine clearance and provided adequate
precautions are taken.

Further precautions in rheumatoid arthritis
Since ciclosporin may reduce renal function, a reliable baseline for serum creatinine
in at least to measurements should be established before treatment. Afterwards, serum
creatinine levels should be monitored weekly for one month. Thereafter serum
creatinine should be monitored every two weeks in the first 3 months of treatment and
thereafter once a month. More frequent control is required when the ciclosporin dose
is increased, if concomitant treatment with a non-steroidal anti-inflammatory
substance is initiated or increased.
If serum creatinine levels are more than 30% above baseline in several measurements,
the dose of Capsorin should be reduced. If serum creatinine levels increase by more
than 50%, the dose should be reduced by 50%. These recommendations apply even if
values are within the laboratory normal range. If serum creatinine levels do not
decrease within one month, treatment with Capsorin should be discontinued.
Treatment should also be discontinued if treatment-emergent hypertension cannot be
controlled with appropriate antihypertensive treatment.

As with other long immunosuppressive treatments there is an increased risk of
lymphoproliferative disturbances. Caution is advised if ciclosporin is used
concomitantly with methotrexate.
When treating rheumatoid arthritis, and taking into consideration the safety of the
patient, additional controls should be carried out in accordance with the following
time frame:
- haematology profile (red blood count, leucocyte and thrombocyte counts): primary
and thereafter every 4 weeks
- liver enzymes: primary and thereafter every 4 weeks
- urine status: primary and thereafter every 4 weeks
- blood pressure: primary and thereafter every 2 weeks for 3 months. Afterwards,
every 4 weeks.
- potassium, lipids: primary and thereafter every 4 weeks.
Experience is available from clinical studies for a period of up to 12 months. There is
currently insufficient experience for longer treatment periods. If there is no
perceptible effect after 3 months of treatment, administration with Capsorin should be

Further precautions in psoriasis
Since ciclosporin may reduce the renal function, a reliable baseline for serum
creatinine in at least two measurements should be established before the treatment,
and serum creatinine should be monitored every 2 weeks in the first 3 months of the
treatment and thereafter once a month. If serum creatinine levels increases to more
than 30% above baseline and are continually increased in more than one
measurement, Capsorin dose should be reduced by 25 to 50%. If serum creatinine
level increases by more than 50%, the dose should be reduced by 50%. These
recommendations apply even if values are within the normal laboratory range. If
serum creatinine levels do not decrease within one month, treatment with Capsorin
should be discontinued.
The treatment should also be discontinued if treatment emergent hypertension cannot
be controlled with appropriate antihypertensive treatment.
Elderly patients should only be treated if their psoriasis is debilitating and their renal
function should be monitored carefully.
The duration of use is normally 12 weeks. Insufficient experience exists with
treatment regimens longer than 24 weeks in duration. Termination of the treatment is
recommended if high blood pressure which cannot be adequately controlled occurs
during treatment with Capsorin.
Development of malignant growths (especially of the skin) has been reported in
psoriasis patients receiving treatment with ciclosporin as well as those treated with
traditional immunosuppressants. A scan for all forms of pre-existing tumours,
including those of the skin and cervix, should be carried out. A biopsy should be

performed before starting Capsorin treatment on skin lesions which are not typical for
psoriasis to exclude skin cancers, mycosis fungoides or other premalignant disorders.
Patients with malignant or premalignant skin alterations should only be treated with
ciclosporin after appropriate treatment of these lesions and only if there is no
alternative treatment.
A small number of psoriasis patients on ciclosporin treatment have developed
lympho-proliferative disturbances which were reversible by immediate
discontinuation of treatment. Patients treated with Capsorin should not receive
concomitant irradiation treatment with UV-B-radiation or PUVAphotochemotherapy.
In view of the potential risk of skin malignancy, patients on Capsorin should be
warned to avoid excessive unprotected sun exposure.

Further precautions in atopic dermatitis
Since ciclosporin may reduce the renal function, a reliable baseline for serum
creatinine in at least two measurements should be established before the treatment,
and serum creatinine should be monitored every 2 weeks in the first 3 months of the
treatment and thereafter once a month. If serum creatinine levels increase to more
than 30% above baseline and are continuously increased in more than one
measurement, the dose of Capsorin should be reduced by 25-50%. These
recommendations apply even if values are within the normal laboratory range. If
serum creatinine levels do not decrease within one month treatment with ciclosporin
should be discontinued.
Treatment should also be discontinued if treatment emergent hypertension cannot be
controlled with appropriate antihypertensive treatment.
Since experience with ciclosporin in children with atopic dermatitis is limited,
Capsorin is not recommended for use in children.
Elderly patients should only be treated if their atopic dermatitis is debilitating, and
their renal function should be monitored carefully.
Benign lymphadenopathy is often connected with flare-up of atopic dermatitis and
disappears spontaneously or with improvement in the disease. Lymphadenopathy
observed in association with ciclosporin treatment should be monitored carefully. If
lymphadenopathy continues despite improvement, a preventive biopsy should be
made to exclude the possibility of lymphoma.
Active Herpes simplex infections should be eliminated before treatment with
ciclosporin is initiated, but discontinuation of ciclosporin treatment is only warranted
if severe infection develops during treatment.

Skin infections with Staphylococcus aureus are not an absolute contra-indication for
treatment with Capsorin, but should be treated with appropriate antibacterial drugs.
Oral erythromycin may increase the blood concentration of ciclosporin (see section
4.5. Interaction with other medicinal products and other forms of interaction) and
should therefore be avoided. If there is no alternative available, blood concentrations
of ciclosporin, renal function and possible adverse reactions to ciclosporin should be
monitored closely.
Since there is a potential risk of malignant skin growths, patients treated with
ciclosporin should be cautioned against exposure to sunlight without protection.
These patients should not receive concomitant radiotherapy with UVB radiation or
PUVA photochemotherapy.
Capsorin contains 12.7 vol% ethanol (alcohol), i.e. up to 525mg per dose, equivalent
to 13ml beer, 6ml wine per dose. Harmful for those suffering from alcoholism. To be
taken into account in pregnant or breast-feeding woman, children and high-risk
groups such as patients with liver disease, or epilepsy.


Interaction with other medicinal products and other forms of interaction
Interaction with foods
Concomitant administration of grapefruit juice has been shown to increase the
bioavailability of ciclosporin.
Interaction with other medicines
The section below list the medicines for which an interaction with Ciclosporin has
been sufficiently proven and is considered to be clinically relevant.
Different medicines either increase or decrease the plasma or whole blood
concentration of ciclosporin, usually by inhibition or induction of enzymes involved
in the metabolism of ciclosporin (particularly cytochrome P450)
The product contains ethanol (see section 4.4). Ethanol may interact with other
medicinal products.
Medicines which reduce ciclosporin concentrations
Barbiturates, carbamazepine, phenytoin; phenobarbital; primidone; griseofluvin;
metamizole; nafcillin, sulfadimidine and trimethoprim i.v.; rifampicin; octreotide;
probucol; sulphadiazine, orlistat, troglitazone, Hypericum perforatum (St John's
Wort), ticlopidine.
Patients on ciclosporin treatment should not use products/herbal medicines, which
contain Hypericum perforatum, since this may cause a marked reduction in plasma
concentrations of ciclosporin by induction of CYP3A4, and thus a diminution of
therapeutic efficacy (see 4.3 Contraindications).
Medicines which increase ciclosporin concentrations:
Macrolide antibiotics (mainly erythromycin, clarithromycin, josamycin,
roxithromycin and pristinamicin); ketoconazole, fluconazole, itraconazole; calcium
antagonists (such as diltiazem, nicardipine, verapamil); metoclopramide; oral
contraceptives; propafenone; danazol; methylprednisolone (high dose); allopurinol;

anti-H2 (cimetidine, ranitidine); chloroquine; amiodarone; bromocriptine; protease
inhibitors, doxycycline.
Other relevant forms of interaction with other medicines
Caution is advised when the concomitant use of other medicines with ciclosporin
results in nephrotoxic synergy: aminoglycosides (including gentamicin, tobramycin),
amphotericin B, ciprofloxacin, vancomycin, trimethoprim (+ sulfamethoxazole); nonsteroidal anti-inflammatory substances (including diclofenac, naproxen, sulindac);
melphalan, tacrolimus and sirolimus.
During treatment with ciclosporin vaccinations may be less effective, so the use of
live weakened vaccine should be avoided.
Concomitant administration of nifedipine and ciclosporin may exacerbate the gingival
hyperplasia that is seen when ciclosporin is used alone.
When combining Ciclosporin with corticosteroids, methylprednisolone, prednisone,
or prednisolone, an increased risk of brain seizures has been reported. This is
especially true for high doses of corticosteroids.
Concomitant use of diclofenac and ciclosporin has shown to cause a pronounced
increase in the bioavailability of diclofenac, which may cause reversible reduced
renal function. The increase in the bioavailability of diclofenac is most probably due
to a reduction in the high first-pass effect of diclofenac. If non-steroidal antiinflammatory substances with a low first-pass effect (e.g. acetylsalicylic acid) are
used concomitantly with ciclosporin, no increase in bioavailability is expected.
Ciclosporin may also reduce the excretion of digoxin, colchicine, lovastatin,
pravastatin, simvastatin, atorvastatin and prednisolone and may therefore lead to
digoxin toxicity or increase the risk of muscle toxicity (including muscle pain and
weakening, myositis and occasionally rhabdomyolysis) due to colchicin, lovastatin,
pravastatin, simvastatin and atorvastatin.
If concomitant use of medicines which have an interaction with ciclosporin in
unavoidable, the following basic recommendations should be followed:
During concomitant use of medicines which cause nephrotoxic synergy, renal
function (especially serum creatinine) should be monitored carefully. If renal function
is considerably reduced, the dose of the concomitant medicine should be decreased or
an alternative treatment should be considered.
Medicines which are known to reduce or increase the bioavailability of ciclosporin
In transplant patients frequent measurement of ciclosporin concentrations is required
with possible dose adjustment, especially during initiation of treatment or at
discontinuation of the concomitant medicine. In non-transplant patients, the value of
monitoring blood concentrations of ciclosporin is doubtful, since the relationship
between blood concentration and clinical effect is not well established. If medicines
which increase the ciclosporin concentrations are used concomitantly, it may be more
useful to measure renal function frequently and to monitor the patient carefully with
regards to ciclosporin related adverse reactions.
Concomitant use of nifedipine should be avoided in patients with gingival

Non-steroidal anti-inflammatory substances which are known to have a marked firstpass metabolism (e.g. diclofenac) should be given at a lower dose than that normally
recommended for patients not receiving ciclosporin.
As hepatotoxicity is a potential side effect of non-steroidal anti-inflammatory drugs,
regular monitoring of hepatic function is advised when Ciclosporin is co-administered
with these drugs in rheumatoid arthritis patients.
If digoxin, colchicine, lovastatin, pravastatin or simvastatin are used concomitantly
with ciclosporin, careffuly clinical monitoring is required.


Fertility, pregnancy and lactation
Experience with ciclosporin in pregnant women is limited.
Ciclosporin does not demonstrate teratogenicity in experimental animals. Limited
experience regarding the safety of administration of ciclosporin to pregnant women has
shown no indications of teratogenicity. Ciclosporin does pass into the placenta. Initial
experience with transplantation patients, however, did indicate that ciclosporin, as with
other immunosuppressive agents, increases the probability of specific complications
during pregnancy, such as pre-eclampsia and premature births with decreased birth
Ciclosporin should be given during pregnancy only when the benefits outweigh the
risks. Pregnant women who are being treated with Ciclosporin should be observed
Ciclosporin is excreted in the breast milk. Women receiving Ciclosporin treatment
should not breastfeed.


Effects on ability to drive and use machines
No data exist on the effects of ciclosporin on ability to drive and use machines.
The product contains ethanol (see section 4.4). Ethanol may have an influence on the
ability to drive and use machines.


Undesirable effects
Many of the adverse reactions to ciclosporin are dose dependent and can be avoided by
dose reduction. The adverse reactions are generally the same in the different
indications, but occur at different frequencies. Since a higher initial dose and longer
maintenance treatment is required after transplantation, adverse reactions are seen more
frequently and are usually more severe in transplant patients than in patients treated for
other indications.
Frequency estimates:
Very common (≥1/10)
Common (≥1/100 to <1/10)
Uncommon (≥1/1,000 to <1/100)
Rare (≥1/10,000 to <1/1,000)

Very rare (<1/10,000)
Not known (cannot be estimated from the available data)
Blood and lymphatic system disorders
Uncommon: Anaemia, thrombocytopenia.
Rare: Microangiopathic haemolytic anaemia, haemolytic uraemic syndrome.
Endocrine disorders
Uncommon: In some patients malignant neoplasia or lymphoproliferative diseases have
been reported, with incidence and distribution similar to those in patients receiving
tradicional immunosupressive therapy.
Rare: Menstrual disturbances, gynecomastia.
Metabolism and nutrition disorders
Very common: Hyperlipidaemia, hypercholesterolaemia.
Common: Hyperuricaemia, hyperkalaemia, hypomagnesaemia.
Rare: Hyperglycaemia.
Nervous system disorders
Very common: Tremor, headache.
Common: Paresthesia.
Uncommon: Signs of encephalopathy, e.g. convulsion, confusion, disorientation,
decreased responsiveness, agitation, insomnia, visual disturbances, cortical blindness,
coma, paresis, cerebellar ataxia.
Rare: Motor polyneuropathy.
Very rare: Oedema in the visual pupil, including disk oedema with possible visual
weakening following benign intracranial hypertension.
Vascular disorders
Very common: hypertension
Gastrointestinal disorders
Common: Anorexia, nausea, vomiting, abdominal pain, diarrhoea, gingival hyperplasia.
Hepatobiliary disorders
Common: Hepatic dysfunction.
Rare: Pancreatitis.
Skin and subcutaneous tissue disorders
Common: Hypertrichosis.
Uncommon: Allergic rash.
Musculoskeletal and connective tissue disorders
Common: Muscle cramps, myalgia.
Rare: Muscle weakness, myopathy.
Renal and urinary disorders
Very common: Renal dysfunction (see 4.4 Special warnings and precautions for use).
General disorders and administration site conditions
Common: Fatigue.
Uncommon: Oedema, weight gain.


a) Symptoms of intoxication
Little experience exists with overdose.
After ingestion of doses up to 10 g ciclosporin (approximately 150 mg/kg), vomiting,
somnolence, headache, tachycardia and in some patients a moderately severe,
reversible kidney dysfunction was observed. There have been reports of severe
intoxication symptoms with preterm infants after inadvertent parenteral overdose.
b) Therapy of intoxication
Possible signs of nephrotoxicity are reversible in most cases after discontinuation of
administration of Capsorin. In case of an overdose, symptomatic treatment and
general supportive measures should be applied. Ciclosporin is not dialyzable nor is it
eliminated by activated charcoal-haemoperfusion therapy.
Therefore, elimination is limited to non-specific treatment, e. g. gastrolavage.
However, activated charcoal eliminates small amounts of ciclosporin from the
enterohepatic circulation. Within the first few hours after overdose, it may be
beneficial for the patient to induce vomiting.



5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Immunosuppressants
ATC code: L04 AD 01.
Mechanism of action
Ciclosporin (also called cyclosporine A) is a cyclic poly peptide, which consists of 11
amino acids. It is a strong immunosuppressive substance, which in animals increases the
survival of allogenic transplantations of skin, heart, kidneys, pancreas, bone marrow,
small intestine and lungs. Studies show that ciclosporin inhibits the development of cellmediated reactions, including allotransplantation immunity, delayed skin hypersensitivity,
experimental allergic encephalomyelitis, Freund’s adjuvant arthritis, graft-versus-host
disease (GVHD) and the production of T-cell dependent antibodies. At the cellular level
ciclosporin inhibits the production and release of lymphokines, including interleukin 2 (Tcell growth factor, TCGF). Ciclosporin apparently blocks the resting lymphocytes in
phase G0 or G1 in the cell cycle and inhibits the antigen triggered release of lymphokines
from activated T-cells.
Pharmacodynamic effects
The existing evidence indicates that ciclosporin acts specifically and reversibly on
lymphocytes. Contrary to cytostatic agents, ciclosporin does not suppress haemopoiesis
and has no effect on phagocytic cell function. Patients treated with ciclosporin are less
susceptible to infections than those treated with other immunosuppressants.
Clinical efficacy and safety
Successful organ and bone marrow transplantations have been carried out in humans,
where ciclosporin has been used to prevent and treat rejection and GVHD.

Treatment with ciclosporin has also shown to be advantageous in a series of other
conditions with a known autoimmune origin or considered to be of autoimmune origin.


Pharmacokinetic properties

The maximal blood concentration (Cmax) is achieved within 1-2 hours (Tmax). The absolute
bioavailability is 30-60%. The inter- and intra-individual pharmacokinetic variability is 1020% for AUC and Cmax in healthy volunteers. Ciclosporin can be administered with food or
The results of several studies have shown that monitoring of the ciclosporin area under the
time-concentration curve for the first 4 hours after administration of dose (AUC0-4) gives a
more precise prediction of the ciclosporin exposure than at base (C0) monitoring.
The results from further studies indicate that a single test point 2 hours after the dose (C2)
correlate well with the AUC0-4 in transplantation patients.
In medical practice either trough level monitoring or C2 monitoring of ciclosporin can be used
for pharmacotherapeutic surveillance.
Ciclosporin is mainly distributed outside the blood volume. In the blood there is 33-47%
ciclosporin in plasma, 4-9% in the lymphocytes, 5-12% in the granulocytes and 41-58% in the
erythrocytes. In plasma approximately 90% is bound to proteins, mainly lipoproteins.
Ciclosporin is biotransformed by several metabolic routes into approximately 15 metabolites.

The elimination is mainly biliary, where only 6% of an oral dose is eliminated with the urine.
Only 0.1% is eliminated unchanged in the urine.
There is a great variation in the available data regarding the terminal half life of ciclosporin
depending on the analysis and the target population. The terminal half life varied from 6.3
hours in healthy volunteers to 20.4 hours in patients with severe hepatic disease.


Preclinical safety data
Ciclosporin showed no mutagenic or teratogenic effects in appropriate test systems.
Reproduction studies in rats showed only negative effects at doses, which were toxic
for the females. At toxic doses (rats 30mg/kg and rabbits 100mg/kg/day orally),
ciclosporin was embryo- and foeto-toxic, which was indicated by increased prenatal
and postnatal mortality and reduced foetal weight and bone formation.
Within the well-tolerated dose range (in rats up to 17 mg/kg/day and in rabbits up to
30mg/kg/day orally), ciclosporin showed no embryo-lethal or teratogenic effects.
Carcinogenicity studies were carried out in male and female rats and mice. In the
mouse study, which lasted 78 weeks, there was a statistically significantly greater

incidence of lymphocytic lymphomas in female mice at a dose of 1, 4, and
16mg/kg/day and a considerably higher occurrence of hepatocellular carcinomas in
male mice, compared to control animals. In the rat study, which lasted 24 months and
involved a dose of 0.5, 2 and 8mg/kg/day, the incidence of island cell adenomas in
the pancreas considerably exceeded the control value at the low dose. Hepatocellular
carcinomas and island cell adenomas in the pancreas were not dose related.
Studies in male and female rats showed no reduction in fertility.
Ciclosporin was not found to be mutagenic/genotoxic in the Ames test, the V79HGPRT test or the micronucleus test in mice and Chinese hamsters or the
chromosome aberration test of the bone marrow of Chinese hamster, the dominating
mortality analysis in mice and the DNA repair test in semen from treated mice. An in
vitro analysis of sister chromatid exchange (SCE) in human lymphocytes showed a
positive effect of ciclosporin at high doses in this system.
An increased occurrence of malignant growths is a recognised complication in
connection with immunosuppression in organ transplant patients. The most common
forms of neoplasms are non-Hodgkin's related lymphomas and skin carcinomas. The
risk of malignant growths during treatment with ciclosporin is higher than in a normal
healthy population, but is similar to the risk for patients treated with other
immunosuppressants. Reports that reduction or discontinuation of
immunosuppressants may cause regression of lesions are available.




List of excipients
Ethanol, anhydrous
Tocopherol acetate
Diethylene glycol monoethyl ether
Oleoyl macrogolglycerides
Macrogolglycerol hydroxystearate


Not applicable.


Shelf life
3 years
The oral solution should be used within 2 months after first opening.


Special precautions for storage
Do not store above 25ºC.


Nature and contents of container
Amber glass bottles type III, available in 50 ml with plastic cover and aluminium cap.
Dispenser sets are also provided, one for adult and other for paediatric use.
Capsorin100 mg/ml oral solution is available in pack size of 1 bottle of 50 ml.


Special precautions for disposal

1) Raise flap on top of the metallic sealing ring
2) Tear off sealing ring completely
3) Remove rubber stopper from bottle and dispose of it carefully
4) Insert the tube with attached white stopper into the bottle, and press until the
stopper is firmly into the neck of the bottle
5) Insert the nozzle of syringe (doser) into the white stopper
6) Draw up the plunger until the medicine rises up the syringe to the dosage level
prescribed by your doctor
7) If any larger bubbles of air appear in the syringe, push the plunger all the way
down and aspirate the solution with various times to force the bubbles out. After
the large bubbles are gone, measure the prescribed solution volume again. The
presence of a few tiny bubbles will not affect the dosing in any way
8) After use, clean the exterior of the syringe with a clean dry tissue and return to its
protective cover. The white stopper and tube should remain permanently in the
bottle. Close bottle with the screw-top

Next use: The next time you use your medicine, start at Point 5


Morningside Healthcare Ltd
115 Narborough Road


PL 20117/0043





+ Expand Transcript

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.